Over the last 7 days, the U.S. market has dropped by 2.7%, yet it has risen by 23% over the past year, with earnings forecasted to grow annually by 17%. For investors interested in smaller or newer companies, penny stocks — despite being an older term — remain relevant as they can offer surprising value and growth potential when backed by strong financials. This article highlights several penny stocks that stand out for their financial strength, presenting opportunities for those seeking under-the-radar companies with promising long-term prospects.

Here we highlight a subset of our preferred stocks from the screener.

OPKO Health (OPK)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: OPKO Health, Inc. is a healthcare company operating in the United States, Ireland, Chile, Spain, Israel, Mexico and internationally with a market cap of $1.09 billion.

Operations: The company's revenue is primarily derived from its Diagnostics segment, which generated $339.62 million, and its Pharmaceutical segment, contributing $241.51 million.

Market Cap: $1.09B

OPKO Health, Inc. has faced challenges with profitability, reporting a net loss of US$54.85 million for Q1 2026, though this is an improvement from the previous year's loss. The company projects total revenue between US$530 and US$560 million for 2026, indicating stable revenue expectations despite a decline in Q1 earnings compared to the prior year. While OPKO's debt levels have increased over five years, its short-term assets cover both short- and long-term liabilities comfortably. The management team is experienced with an average tenure of 9.3 years, providing stability amidst ongoing financial hurdles.

Sight Sciences (SGHT)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Sight Sciences, Inc. is an ophthalmic medical device company that develops and commercializes surgical and nonsurgical technologies for treating prevalent eye diseases in the United States, with a market cap of $242.12 million.

Operations: Sight Sciences generates revenue from two primary segments: Interventional Glaucoma, which accounts for $76.95 million, and Interventional Dry Eye, contributing $2.60 million.

Market Cap: $242.12M

Sight Sciences, Inc. has shown revenue growth in its recent earnings report, with Q1 2026 sales increasing to US$19.7 million from US$17.51 million a year ago, while reducing its net loss to US$12.98 million. Despite being unprofitable and experiencing high share price volatility, the company maintains a strong cash position exceeding its total debt and covers both short- and long-term liabilities with available assets. The management team is experienced, contributing to strategic stability as it raises revenue guidance for 2026 amidst ongoing product developments in glaucoma and dry eye treatment technologies.

Nu Ride (NRDE)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nu Ride Inc. currently does not have significant operations and has a market cap of $26.40 million.

Operations: Nu Ride Inc. has not reported any revenue segments at this time.

Market Cap: $26.4M

Nu Ride Inc., with a market cap of US$26.40 million, is currently pre-revenue and unprofitable, though it has significantly reduced its losses over the past five years by 40.9% annually. The company reported a net loss of US$0.108 million for Q1 2026, down from US$1.21 million a year earlier, indicating progress in financial management despite lacking significant operations or revenue streams. Nu Ride is debt-free and maintains sufficient short-term assets (US$35.4M) to cover liabilities (US$3.2M), providing a cash runway exceeding three years under stable conditions, although share price volatility remains high compared to most U.S stocks.

Seize The Opportunity

• Investigate our full lineup of 332 US Penny Stocks right here.
• Searching for a Fresh Perspective? These 24 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.